Company Description
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.
The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products.
In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices.
Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures.
It sells its products through direct sales, service forces, independent distributors, and sales representatives.
Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
| Country | United States |
| IPO Date | Jun 21, 1990 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 6,990 |
| CEO | Stephen P. MacMillan |
Contact Details
Address: 250 Campus Drive Marlborough, Massachusetts 01752 United States | |
| Phone | (508) 263-2900 |
| Website | hologic.com |
Stock Details
| Ticker Symbol | HOLX |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000859737 |
| CUSIP Number | 436440101 |
| ISIN Number | US4364401012 |
| Employer ID | 04-2902449 |
| SIC Code | 3844 |
Key Executives
| Name | Position |
|---|---|
| Stephen P. MacMillan | Chairman, Chief Executive Officer and President |
| Karleen M. Oberton | Chief Financial Officer |
| Essex D. Mitchell | Chief Operating Officer |
| John M. Griffin | General Counsel |
| Jan Verstreken | Group President of International |
| Paul Malenchini | Chief Information Officer |
| Ryan M. Simon | Vice President of Investor Relations |
| Peter P. Dunne | Senior Vice President of Human Resources |
| Monica Aguirre Berthelot | Vice President and Chief of Staff |
| Erik S. Anderson | Division President of Breast and Skeletal Health Solutions |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2024 | 144 | Filing |
| Mar 12, 2024 | 8-K | Current Report |
| Mar 8, 2024 | 144 | Filing |
| Mar 8, 2024 | 144 | Filing |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | 10-Q | Quarterly Report |
| Feb 1, 2024 | 8-K | Current Report |
| Jan 29, 2024 | 144 | Filing |
| Jan 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |